New nanoparticle therapy targets bladder cancer cells

NCT ID NCT06173349

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment called PLZ4-coated paclitaxel-loaded micelles (PPM) for people with non-muscle invasive bladder cancer that has come back or not responded to standard therapy. PPM is a nanoparticle designed to deliver chemotherapy directly to tumor cells in the bladder. The study will enroll 12 participants to check safety and see if the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PLZ4-coated paclitaxel-loaded micelles (PPM)
What this could lead to: If successful, this could provide a new targeted treatment option for bladder cancer that has not responded to standard therapy, potentially reducing the need for bladder removal.
What could go wrong: This is a very early Phase I trial with only 12 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NON-MUSCLE INVASIVE BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT NON-MUSCLE INVASIVE BLADDER CARCINOMA STAGE 0A BLADDER CANCER AJCC V8 STAGE 0IS BLADDER CANCER AJCC V8 STAGE I BLADDER CANCER AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.